Vischer advised Ikerian, a healthcare software platform company, on its first round of USD 8m Series B financing to advance its AI platform. The Series B financing round is led by strategic investor Sanoptis led
Tags :Timothy Woodtli
The Swiss dental startup Odne has raised USD 5.5m to fund the upcoming US market launch for their minimal invasive Root Preservation Technology (RPT). The Series A1 round for Odne, was led by Revere Partners (
GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional investment by Bristol Meyer Squibb (BMS) to further support the development of its innovative platform to enable high-throughput design
Proteomedix, a Swiss private, commercial-stage diagnostics oncology company and Water Biotech are forming together a company called Onconetix. The transaction is implemented by the acquisition of Proteomedix for an all stock consideration. Onconetix’s commercial
Oculis Holding, a global biopharmaceutical company purposefully driven to save sight and improve eye care, has placed a follow-on public offering of 3.5m ordinary shares at a public offering price of USD 11.50 per ordinary share,
Mosanna Therapeutics, a Basel-based biotechnology company developing the highly differentiated small molecule MOS118 for the treatment of metabolic obstructive sleep apnea, has closed an extension of the Seed Financing Round with the investors Supermoon Capital,
Oculis Holding, a global biopharmaceutical company, purposefully driven to save sight and improve eye care, listed its shares on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp. (“EBAC”). At closing, Oculis
Resistell, a leader in phenotypic nanomotion technology for measuring living cells, based in Muttenz, Switzerland, has taken another major step to achieving its vision by closing a first tranche of its series B financing round
Mosanna Therapeutics, a Basel-based biotechnology company, has closed a Seed Financing Round led by Forty51 Ventures. The proceeds will be used for formulation and manufacturing optimization of the molecule MOS118 and for regulatory activities in
Novaremed, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics, a China-based clinical stage neuroscience biotech company, jointly announced the signing of an exclusive collaboration and commercialization agreement for non-opioid investigational drug, NRD.E1. The
